Melanoma — Research · CancerIndex

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

pubmedComputed14 windows · counts computed by CancerIndex from PubMed E-utilities; the exact query is stored with each count.

Window	Period	Records (count)	Exact query	Computed	Source
All time	… → 2026-09-28	119,835	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh])`	2026-09-28	pubmed
Last 5 years	2021-01-01 → 2026-12-31	20,490	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2021/01/01:2026/12/31[dp])`	2026-09-28	pubmed
Preceding 5-year window	2020-09-28 → 2025-09-27	18,986	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2020/09/28:2025/09/27[dp])`	2026-09-28	pubmed
Last 12 months	2025-09-28 → 2026-09-28	3,010	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2025/09/28:2026/09/28[dp])`	2026-09-28	pubmed
y2016	2016-01-01 → 2016-12-31	4,158	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2016/01/01:2016/12/31[dp])`	2026-09-28	pubmed
y2017	2017-01-01 → 2017-12-31	4,377	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2017/01/01:2017/12/31[dp])`	2026-09-28	pubmed
y2018	2018-01-01 → 2018-12-31	4,312	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2018/01/01:2018/12/31[dp])`	2026-09-28	pubmed
y2019	2019-01-01 → 2019-12-31	4,427	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2019/01/01:2019/12/31[dp])`	2026-09-28	pubmed
y2020	2020-01-01 → 2020-12-31	4,719	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2020/01/01:2020/12/31[dp])`	2026-09-28	pubmed
y2021	2021-01-01 → 2021-12-31	4,665	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2021/01/01:2021/12/31[dp])`	2026-09-28	pubmed
y2022	2022-01-01 → 2022-12-31	4,355	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2022/01/01:2022/12/31[dp])`	2026-09-28	pubmed
y2023	2023-01-01 → 2023-12-31	4,311	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2023/01/01:2023/12/31[dp])`	2026-09-28	pubmed
y2024	2024-01-01 → 2024-12-31	3,904	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2024/01/01:2024/12/31[dp])`	2026-09-28	pubmed
y2025	2025-01-01 → 2025-12-31	3,544	`("Melanoma"[mh] OR "Malignant Melanomas"[mh] OR "Melanomas"[mh]) AND (2025/01/01:2025/12/31[dp])`	2026-09-28	pubmed

Data updated 3 days agoSource updated unknownsource: pubmed E-utilities

Literature

Linked publications (195)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedPublishedShowing 51–75 of 195 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Improved overall survival in melanoma with combined dabrafenib and trametinib.
· N Engl J Med · 2015 · PMID 25399551 · validated civic_curation pubmed
Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial.
· Lancet Oncol · 2016 · PMID 27480103 · validated civic_curation pubmed
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.
· Lancet Oncol · 2018 · PMID 29573941 · validated civic_curation pubmed
Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial.